Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2017 | Lenalidomide and ibrutinib: do they have a future in treating CLL?

Nitin Jain • 2 Jun 2017
ASCO 2017
Chronic Lymphocytic Leukemia Ibrutinib Lenalidomide

Nitin Jain, MD, from the University of Texas MD Anderson Cancer Center, Houston, TX, talks to us about the implications of the positive results from clinical trials on treating chronic lymphocytic leukemia (CLL) with lenalidomide in addition to fludarabine and rituximab (NCT00860457), presented at the American Society of Oncology (ASCO) 2017 Annual Meeting in Chicago, IL. The future of treating CLL with combination regimens including ibrutinib (NCT02301156), and the need to re-design clinical trials to consider the complications of Richter’s Transformation in CLL is also discussed here.

More from Nitin Jain

1:13
5-year follow-up of patients with CLL treated in first-line with ibrutinib plus venetoclax
Nitin Jain • 10 Dec 2023
1:06
An ongoing Phase I trial evaluating AS-1763, a novel non-covalent BTKi, in B-cell lymphomas
Nitin Jain • 10 Dec 2023
1:43
Long-term outcomes of the iFCG regimen for firstline treatment of patients with IGHV-mutated CLL
Nitin Jain • 10 Dec 2023
1:54
Nivolumab + ibrutinib for patients with Richter’s transformation
Nitin Jain • 7 Sep 2023

Related Videos

3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
3:18
A Phase I study of JBH492, an anti-CCR7 antibody-drug conjugate, in lymphoid malignancies
Pau Abrisqueta • 5 Apr 2024
0:44
Early detection and interception across hematological cancers
Irene Ghobrial • 8 Apr 2024
1:21
Monoclonal B-cell lymphocytosis: a disease to be (or not to be)
Paolo Ghia • 7 Apr 2024
The content of VJHemOnc is intended for healthcare professionals